Cardiac Amyloidosis – An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction – Updated Diagnosis and Treatment Options

Rimbas, Roxana Cristina; Balinisteanu, Anca; Chitroceanu, Alexandra Maria; Vinereanu, Dragos

doi:10.47803/rjc.2021.31.2.283

Abstract

Cardiac amyloidosis (CA) still represents a frequently missed cause of heart failure with preserved ejection fraction (HFpEF). In the light of many new and effective therapies for immunoglobulin light chain amyloidosis (AL) and for transthyretin amyloidosis (ATTR), screening for amyloidosis as an important and potentially treatable diagnosis under the HFpEF becomes mandatory. A step-by-step algorithm for CA in HF patients was already provided by the guidelines. This review summarizes the role of all imaging modalities and biomarkers in the diagnosis and prognosis of both subtypes, the algorithm for diagnosis of CA, and new therapeutic options. It is the first Romanian publication which intends to bring altogether the current recommendations in the diagnosis and management of CA.

References

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JCF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC scientific document group. Eur Heart J. 2016; 37:2129–200.
Search in Google Scholar Back to article
Bieske P, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancelloti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowsky P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitza F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 2019; 40:3297–317.
Search in Google Scholar Back to article
Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, BauerSachs J, Burkhoff D, Bonow RO, Chopra VK, de Boer RA, de Windt L, Hamdani N, Hasenfuss G, Heymans S, Hulot JS, Konstam M, Lee RT, Linke WA, Lunde IG, Lyon AR, Maack C, Mann DL, Mebazaa A, Mentz RJ, Nihoyannopoulos P, Papp Z, Parisiss J, Pedrazzini T, Rosano G, Rouleau J, Seferovic PM, Shah AM, Starling RC, Tocchetti CG, Trochu JN, Thum T, Zannad F, Brutsaert DL, Segers VF, De Keulenaer GW. The continuous heart failure spectrum: moving beyond an ejection fraction classification. Eur Heart J. 2019; 40:2155–63.
Search in Google Scholar Back to article
Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, Shinriki S, Kawahara S, Jono H, Obayashi K, Ogawa H, Ando Y. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol 2011; 24:1533–44.
Search in Google Scholar Back to article
Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, Haro Del-Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36:2585–94.
Search in Google Scholar Back to article
Scully PR, Treibel TA, Fontana M, Lloyd G, Mullen M, Pugliese F, Hartman N, Hawkins PN, Menezes LJ, Moon JC. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018; 71:463–4.
Search in Google Scholar Back to article
Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN, Moon JC. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9:e005066
Search in Google Scholar Back to article
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021; 42:1554–68.
Search in Google Scholar Back to article
Bennani Smires Y, Victor G, Ribes D, Berry M, Cognet T, Mejean S, Huart A, Roussel M, Petermann A, Roncalli J, Carrie D, Rousseau H, Berry I, Chauveau D, Galinier M, Lairez O. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Card Imaging. 2016; 32:1403–13.
Search in Google Scholar Back to article
Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D, Vorobiof G. Cardiac amyloidosis: diagnosis and treatment strategies. Curr Oncol Rep 2017; 19:46.
Search in Google Scholar Back to article
Mohammed SF, Mirzovev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014; 2:113–22.
Search in Google Scholar Back to article
Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 2015; 12:91–102.
Search in Google Scholar Back to article
Gertz MA. Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol 2018; 93:1169–80.
Search in Google Scholar Back to article
Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015; 20:163–78.
Search in Google Scholar Back to article
Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015; 278:126–44.
Search in Google Scholar Back to article
Sandra Ihne, Caroline Morbach, Laura Obici, Giovanni Palladini, Stefan Störk. Amyloidosis in Heart Failure. Curr Heart Fail Rep. 2019; 16:285–303.
Search in Google Scholar Back to article
Benson MD, Dasgupta MR. Amyloid cardiomyopathy. J Am Coll Cardiol 2016; 68:25–8.
Search in Google Scholar Back to article
Gertz MA. Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol 2018; 93:1169–80.
Search in Google Scholar Back to article
Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy A systematic review. JAMA 2020; 324:79–89.
Search in Google Scholar Back to article
Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016; 128:159–68.
Search in Google Scholar Back to article
Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, Rajkumar SV, Vachon CM, Dispenzieri A. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 2019; 94:465–71.
Search in Google Scholar Back to article
Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, Sipe JD, Westermark P. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25:215–9.
Search in Google Scholar Back to article
Arciello A, Piccoli R, Monti DM. Apolipoprotein A-I: the dual face of a protein. FEBS Lett. 2016; 590:4171–9.
Search in Google Scholar Back to article
Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, Rezk T, Youngstein T, Mahmood S, Sachchithanantham S, Lachmann HJ, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Gillmore JD. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017; 38:1905–8.
Search in Google Scholar Back to article
Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001; 98:714–20.
Search in Google Scholar Back to article
Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, Ascari E, Merlini G. Analysis of V (lambda)-J (lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood. 2002; 100:948–53.
Search in Google Scholar Back to article
Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain associated amyloidosis (AL). Blood. 2003; 101:3801–8.
Search in Google Scholar Back to article
Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G. The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012; 119:144–50.
Search in Google Scholar Back to article
Kourelis TV, Dasari S, Theis JD, Ramirez-Alvarado M, Kurtin PJ, Gertz MA, Zeldenrust SR, Zenka RM, Dogan A, Dispenzieri A. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017; 129:299–306.
Search in Google Scholar Back to article
Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, Melzi D’Eril GV, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum Nterminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006; 107:3854–8.
Search in Google Scholar Back to article
Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis. 2018;10: e2018022.
Search in Google Scholar Back to article
Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P. Disease burden of systemic light-chain amyloidosis: a systematic literature review. Curr Med Res Opin. 2017; 33:1017–31.
Search in Google Scholar Back to article
Merlini G, Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN, Gertz MA. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38.
Search in Google Scholar Back to article
Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, Massie R, Narayan J, Swiggum E, Venner CP, Ducharme A, Galant NJ, Hahn C, Howlett JG, Mielniczuk L, Parent MC, Reece D, Royal V, Toma M, Virani SA, Zieroth S. Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol. 2020;36:322–34.
Search in Google Scholar Back to article
Khanna S, Wen I, Bhat A, Chen HHL, Gan GCH, Pathan F, Tan TC. The role of multi-modality imaging in the diagnosis of cardiac amyloidosis: a focused update. Front Cardiovasc Med. 2020;7:212.
Search in Google Scholar Back to article
González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Rev Esp Cardiol. 2017; 70:991–1004.
Search in Google Scholar Back to article
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019; 73:2872–91.
Search in Google Scholar Back to article
Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97:75–84.
Search in Google Scholar Back to article
Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, Koyama J, Yanagisawa S, Ikeda SI. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016; 23:58–63.
Search in Google Scholar Back to article
Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014; 119:223–8.
Search in Google Scholar Back to article
Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2020; 268:2109–22.
Search in Google Scholar Back to article
Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I) cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017; 19:733–42.
Search in Google Scholar Back to article
Agha AM, Parwani P, Guha A, Durand JB, Iliescu CA, Hassan S, Palaskas NL, Gladish G, Kim PY, Lopez-Mattei J. Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. Open Heart. 2018;5:e000881–e000881
Search in Google Scholar Back to article
Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure. Arch Intern Med 2005; 165:1425–9.
Search in Google Scholar Back to article
Perfetto F, Bergesio F, Emdin M, Capelli F. Troponins in cardiac amyloidosis: multipurpose markers. Nat Rev Cardiol. 2014; 11:179.
Search in Google Scholar Back to article
Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med. 2005;118:1287.
Search in Google Scholar Back to article
Dorbala S, Vangala D, Bruyere J, Quarta C, Kruger J, Padera R, Foster C, Hanley M, Di Carli MF, Falk R. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358–67.
Search in Google Scholar Back to article
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017; 135:1357–77.
Search in Google Scholar Back to article
Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Quarta CC, Rapezzi C, Ruberg FL, Witteles R, Merlini G. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12: e006075.
Search in Google Scholar Back to article
Zhongwei Cheng, Kongbo Zhu, Zhuang Tian, Dachun Zhao., Quancai Cui M.D. Quan Fang M.D. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18:157–62.
Search in Google Scholar Back to article
Dungu JN, Sattianayagam PT, Whelan CJ, Gibbs SD, Pinney JH, Banypersad SM, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Hawkins PN, Anderson LJ. The electrocardio graphic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in afro-caribbean patients. Am Heart J 2012; 164:72–9.
Search in Google Scholar Back to article
Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95:535–7.
Search in Google Scholar Back to article
Rahman JE, Helou EF, Gelzer-Bell R, Thompson RE, Kuo C, Rodriguez ER, Hare JM, Baughman KL, Kasper EK. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004; 43:410–5.
Search in Google Scholar Back to article
Austin BA, Duffy B, Tan C, Rodriguez ER, Starling RC, Desai MY. Comparison of functional status, electrocardiographic, and echo car diographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009; 103:1429–33.
Search in Google Scholar Back to article
Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G, Perlini S. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. Ann Noninvasive Electrocardiol. 2013; 18:271–80.
Search in Google Scholar Back to article
Namdar M, Steffel J, Jetzer S, Schmied C, Hurlimann D, Camici GG, Bayrak F, Ricciardi D, Rao JY, de Asmundis C, Chiercia GB, Sarkozy A, Luscher TF, Jenni R, Duru F, Brugada P. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 2012; 109:587–93.
Search in Google Scholar Back to article
Perlini S, Salinaro F, Cappelli F, Perfetto F, Bergesio F, Alogna A, Mussinelli R, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol 2013; 167:2156–61.
Search in Google Scholar Back to article
Granstam SO, Rosengren S, Vedin O, Kero T, Sorensen J, Carlson K, Flachsckampf FA, Wikstrom G. Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization. Amyloid 2013; 20:27–33.
Search in Google Scholar Back to article
Boldrini M, Salinaro F, Mussinelli R, Raimondi A, Alogna A, Musca F, Palladini G, Merlini G, Perlini S. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac al amyloidosis. Ann Noninvasive Electrocardiol 2013; 18:327–35.
Search in Google Scholar Back to article
Reyners AK, Hazenberg BP, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002; 23:157–61.
Search in Google Scholar Back to article
Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014; 7:552–62.
Search in Google Scholar Back to article
Bradshaw SH, Veinot JP. Cardiac amyloidosis. Curr Opin Cardiol 2012; 27:143–7.
Search in Google Scholar Back to article
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lackmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazemberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133:2404–12.
Search in Google Scholar Back to article
Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016; 68:1014–20.
Search in Google Scholar Back to article
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018; 39:2799–806.
Search in Google Scholar Back to article
Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH, Thomas JD. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98:1442–8.
Search in Google Scholar Back to article
Pagourelias ED, Duchenne J, Mirea O, Vovas G, Van Cleemput J, Delforge M, Kuznetsova T, Boagert J, Voigt JU. The relation of ejection fraction and global longitudinal strain in amyloidosis: implications for differential diagnosis. JACC Cardiovasc Imaging. 2016; 9:1358–9.
Search in Google Scholar Back to article
Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, Kuznetsova T, Voigt JU. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017;10: e005588.
Search in Google Scholar Back to article
Ono K, Ishimaru G, Hayashi M, Bae Y, Ito T, Izumo T, Murata K. The imaging diagnosis of less advanced cases of cardiac amyloidosis: the relative apical sparing pattern. Intern Med. 2017; 56:315–9.
Search in Google Scholar Back to article
Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Mohty D, Feux JF, Damy T. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9:126–38.
Search in Google Scholar Back to article
Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, Francis R, Rezk T, Quarta CC, Whelan CJ, Lachmann HL, Wechalekar AD, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Cardiac sructural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC: Cardiovascular Imaging. 2019;12:823–33.
Search in Google Scholar Back to article
Pun SC, Landau HJ, Riedel ER, Jordan J, Yu AF, Hassoun H, Chen CL, Steingart RM, Liu JE. Prognostic and added value of two-dimensional global longitudinal strain for prediction of survival in patients with light chain amyloidosis undergoing autologous hematopoietic cell transplantation. J Am Soc Echocardiogr. 2018;31:64–70.
Search in Google Scholar Back to article
Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL, American Heart Association heart failure and transplantation committee of the council on clinical cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:7–22.
Search in Google Scholar Back to article
Jurcut R, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, Popescu BA. Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging, 2020;21:833–44.
Search in Google Scholar Back to article
Roger-Rollé A, Cariou E, Rguez K, Fournier P, Lavie-Badie Y, Blanchard V, Roncalli J, Galinier M, Carrie D, Lairez O, Toulouse Amyloidosis Research Network collaborators. Can myocardial work indices contribute to the exploration of patients with cardiac amyloidosis? Open Heart 2020;7:e001346.
Search in Google Scholar Back to article
Sakamoto M, Funada A, Amaki M, Ohara T, Hasegawa T, Sugano Y, Kanzaky H, Kitakaze M, Anzai T. More impaired diastolic function of light chain amyloidosis contributes to poor prognosis compared with transthyretin amyloidosis: result from longitudinal study of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2015;65: A935.
Search in Google Scholar Back to article
Stricagnoli M, Cameli M, Incampo E, Lunghetti S, Mondillo S. Speckle tracking echocardiography in cardiac amyloidosis. Heart Fail Rev. 2019; 24:701–7.
Search in Google Scholar Back to article
Clemmensen TS, Eiskjær H, Mikkelsen F, Granstam SO, Flachskampf FA, Sørensen J, Poulsen SH. Left ventricular pressure-strain-derived myocardial work at rest and during exercise in patients with cardiac amyloidosis. J Am Soc Echocardiogr. 2020; 33:573–82.
Search in Google Scholar Back to article
Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7:133–42.
Search in Google Scholar Back to article
Oda S, Utsunomiya D, Nakaura T, Takashio S, Izumiya Y, Tsujita K, Ueda M, Yamashita T, Ando Y, Kawano Y, Okuno Y, Hata H, Yamashita Y. Role of noninvasive diagnostic imaging in cardiac amyloidosis: a review. Cardiovasc Imaging Asia. 2018; 2:97–106.
Search in Google Scholar Back to article
Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 2015; 20:133–44.
Search in Google Scholar Back to article
Wan K, Sun J, Han Y, Liu H, Yang D, Li W, Wang J, Cheng W, Zhang Q, Zeng Z, Chen Y. Increased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosis. Circ J. 2018;82:739–46.
Search in Google Scholar Back to article
Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013; 6:488–97.
Search in Google Scholar Back to article
Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015; 21:244–51.
Search in Google Scholar Back to article
Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46:1076–84.
Search in Google Scholar Back to article
Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SDJ, Venner CP, Wassef N, McCarthy CA, Gillbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2: e000098.
Search in Google Scholar Back to article
Kim D, Choi J-O, Kim K, Kim SJ, Jeon E-S. Untangling amyloidosis: recent advances in cardiac amyloidosis. Int J Heart Fail. 2020; 2:231–9.
Search in Google Scholar Back to article
van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006; 54:2015–21.
Search in Google Scholar Back to article
Swan N, Skinner M, O’Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol. 2003; 120:610–6.
Search in Google Scholar Back to article
Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002; 346:1786–91.
Search in Google Scholar Back to article
Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009; 114:4957–9.
Search in Google Scholar Back to article
Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulus MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121:3420–7.
Search in Google Scholar Back to article
Dispenzieri A, Gertz MA, Kyle Lacy MQ, Burrit MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CGA, Jaffe AS. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004; 104:1881–7.
Search in Google Scholar Back to article
Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli, Obici L, Perlini S, Moratti R, Merlini G. Best use of cardiac biomarkers in patients with AL Amyloidosis and renal failure. Am J Hematol 2012; 87:465–71.
Search in Google Scholar Back to article
Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012; 26:2317–25.
Search in Google Scholar Back to article
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegebart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in Immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol 2012; 30:4541–9.
Search in Google Scholar Back to article
Jercan A., Ene A., Jurcut R, Draghici M, Badelita S, Dragomir M, Dobrea C, Popescu M, Jardan D, Stoica E, Iacob S, Codita I, Stan C, Coriu D. Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population. Orphanet J Rare Dis. 2020; 15:34.
Search in Google Scholar Back to article
Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol. 2020; 27:1456–63.
Search in Google Scholar Back to article
McVeigh T, Tennyson C. Understanding and recognizing cardiac amyloidosis. JAAPA. 2020; 33:16–20.
Search in Google Scholar Back to article
Bonderman D, Polzl G, Ablasser K, Agis H, Aschauer S, Grumbach M, Binder C, Dorler J, Duca F, Ebner C, Hacker M, Kain R, Kammerlander A, Koschutnik M, Kroiss A, Mayr A, Nitsche C, Rainer P, Malmqvist S, Schneider M, Schwarz R, Verheyen N, Weber T, Zaruba M, Eslam R, Hulsmann M, Mascherbauer J. Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr. 2020; 132:742–61.
Search in Google Scholar Back to article
Feng D, Edwards W, Oh J, Chandrasekaran K, Grogan M, Martinez M, Syed I, Hughes D, Lust J, Jaffe A, Gertz M, Klarich K. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007; 116:2420–6.
Search in Google Scholar Back to article
Kapoor P, Thenappan T, Singh E, Kumar S, Greipp P. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011; 124:1006–15.
Search in Google Scholar Back to article
Teng C, Li P, Bae J, Pan S, Dixon R, Liu Q. Diagnosis and treatment of thransthyretin-related amyloidosis cardiomyopathy. Clin Cardiol. 2020; 43:1223–31.
Search in Google Scholar Back to article
Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Bordeneuve V, Schimdt H, Merlini G. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J Am Coll Cardiol. 2015; 66:2451–66.
Search in Google Scholar Back to article
Algalarrondo V, Dinanian S, Juin C, Chemla D, Bennani S, Sebag C, Plante V, Guludec V, Samuel D, Adams D, Slama M. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm 2012; 9:1069–75.
Search in Google Scholar Back to article
Donellan E, Wazni O, Hanna M, Kanj M, Saliba W, Jaber W. Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis. J Am Heart Assoc. 2020;9 e017335.
Search in Google Scholar Back to article
Donellan E, Wazni O, Hanna M, Saliba W, Jaber W, Kanj M. Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis. Pacing Clin Electrophysiol. 2020; 43:1401–3.
Search in Google Scholar Back to article
Priori S, Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot P, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck K, Madrid A, Nikolaou N, Norekval T, Spaulding C, Veldhuisen D. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology. Eur Heart J. 2015; 36:2793–867.
Search in Google Scholar Back to article
Tan N, Mohsin Y, Hodge D, Lacy M, Packer D, Dispenzieri A, Grogan M, Asirvatham S, Madhavan M, McLEOD C. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2016; 27:1167–73.
Search in Google Scholar Back to article
Spoladore R, Falasconi G, Marcatti M, Maio S, Fiore G, Slavich M, Margonato A, Turco A, Fragasso G. Advances in pharmacotherapy for cardiac amyloidosis. Expert Opin Pharmacother. 2020;31:1–13.
Search in Google Scholar Back to article
Kastritis E, Arnulf B, Leieu X, Zamagni E. A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood. 2016;128: 646.
Search in Google Scholar Back to article
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136:71–80.
Search in Google Scholar Back to article
Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan 3rd TH, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431–43.
Search in Google Scholar Back to article
Gertz M, Comenzo R, Landau H, Sanchorawala V, Weiss B, Zonder J, Walling J, Kinney G, Koller M, Schenk D, Guthrie S, Liu E, Liedtke M. NEOD001 demonstrates organ biomarker response in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase ½ study. Blood. 2016; 128:644.
Search in Google Scholar Back to article
Castano A, Helmke S, Alvarez J, Delisle S, Maurer M. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012; 18:315–9.
Search in Google Scholar Back to article
Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL. Stabilization of cardiac function with Diflunisal in transthyretin (ATTR) cardiac amyloidosis. J Card Fail. 2020;26:753–9
Search in Google Scholar Back to article
Maurer M, Schwartz J, Gundapaneni B, Elliot P, Merlini G, Cruz M, Kristen A, Grogan M, Witteles R, Damy T, Drachman B, Shah S, Hanna M, Judge D, Barsdorf A, Huber P, Patterson T, Riley S, Schumacher J, Stewart M, Sultan M, Rapezzi C. ATTR-ACT study investigators: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–16.
Search in Google Scholar Back to article
Endo J, Sano M, Izumyia Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K. A statement on the appropriate administration of Tafamidis in patients with transthyretin cardiac amyloidosis. Circ J 2019;84: 15–7.
Search in Google Scholar Back to article
Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang, CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan 3rd TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.
Search in Google Scholar Back to article
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheiberg M, Brannagan 3rd TH, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.
Search in Google Scholar Back to article
Scully PR, Patel KP, Treibel TA, Thornton GD, Hughes RK, Chadalavada S, Katsoulis M, Hartman N, Fontana M, Pugliese F, Sabharwal N, Newton JD, Kelion A, Ozkor M, Kennon S, Mullen M, Lloyd G, Menezes LJ, Hawkins PN, Moon JC. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41:2759–67.
Search in Google Scholar Back to article
Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion AD, Sabharwal N, Newton JD, Ozkor M, Kennon S, Mullen M, Lloyd G, Fontana M, Hawkins PN, Pugliese F, Menezes LJ, Moon JC, Mascherbauer J, Treibel TA. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77:128–39.
Search in Google Scholar Back to article
Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther 2020; 9:317–33.
Search in Google Scholar Back to article

Cardiac Amyloidosis – An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction – Updated Diagnosis and Treatment Options

Abstract

Paradigm

My account